Law360
6 minute read | September.04.2024
Federal regulators and prosecutors recently prevailed at trial with new and expansive theories of liability in two insider trading cases against executives at public life sciences companies.
In a new article in Law360, Orrick’s Amy Walsh explores what public life sciences companies should know about Securities and Exchange Commission v. Panuwat and United States v. Peizer. In light of the cases, she suggests public life science companies consider: